Home›Ranibizumab Eqrn›Ranibizumab Eqrn + Steroid Therapy

Does Ranibizumab Eqrn Interact with Steroid Therapy?

Ranibizumab Eqrn and Steroid Therapy have a major drug interaction according to U.S. FDA drug labeling data. Serious intraocular inflammation occurred in 11% of patients when ranibizumab was administered 7 days (± 2 days) after PDT. In 10 of 12 cases, inflammation occurred at this timing interval. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Ranibizumab Eqrn Class
Vascular Endothelial Growth Factor Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Ranibizumab Eqrn and your doctor is considering prescribing Steroid Therapy (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Ranibizumab Eqrn(Cimerli)+💊 Steroid Therapy(Monistat Simple Therapy)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Vascular Endothelial Growth Factor Inhibitor
Drug B class
—
Source
NLP:ranibizumab-eqrn

What this means in plain English

Serious intraocular inflammation occurred in 11% of patients when ranibizumab was administered 7 days (± 2 days) after PDT. In 10 of 12 cases, inflammation occurred at this timing interval.

About Ranibizumab Eqrn and Steroid Therapy

Ranibizumab Eqrn is a Vascular Endothelial Growth Factor Inhibitor. Ranibizumab Eqrn is also sold under the brand name Cimerli. Ranibizumab Eqrn is given by the intravitreal route.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Ranibizumab Eqrn and Steroid Therapy against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.